Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK region nears 100% LBC screening

This article was originally published in Clinica

Executive Summary

285,000 (75%) of the 380,000 screens performed annually in the UK's West Midlands region of the NHS use liquid-based cytology (LBC). So said Hologic this week, reporting that nine of the region's 13 screening programmes have now converted from traditional Pap smear screening to LBC ThinPrep Pap Test, developed by Cytyc. "Substantial parts" of another two regions have also converted. The 13 programmes operate through 11 laboratories. All UK women aged 25-64 years are routinely invited for screening once every three years up to the age of 50, and then every five years. Cytyc became a wholly-owned subsidiary of Hologic in October 2007, in a $6.2bn merger (see Clinica No 1279, p 15).

You may also be interested in...



Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.

Moderna Gets To Watch And Learn From Pfizer’s COVID-19 Vaccine Advisory Committee

US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.

Topics

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel